MostlyRollie's. A Cheekyleaf concept
For prescribers

A measured cannabis dose in a format the patient already trusts.

Dose-controlled, batch-traceable, dispensed through pharmacy. Existing inhaled-cannabis evidence applies.

Indications under consideration

Where Mostly Rollie's fits a prescription pathway.

Mostly Rollie's is positioned for patients for whom inhaled cannabis is already a clinically supported route and for whom the unmeasured rolled-joint pattern is the realistic alternative. The launch formulations target three indication areas:

Anxiety

  • Generalised anxiety where pharmacotherapy is appropriate
  • Performance anxiety with episodic dosing
  • Linalool-, myrcene-, limonene-dominant blend

Sleep

  • Sleep-onset disturbance
  • Sleep-maintenance disturbance
  • Myrcene, caryophyllene, with CBN where the cultivar permits

Chronic pain

  • Inflammatory chronic pain
  • Adjunct to existing pain protocols where inhaled cannabis is already in play
  • Caryophyllene, humulene

Indications and formulations are illustrative for the concept stage. Definitive prescribing information accompanies the SAHPRA registration dossier.

Patient suitability

Who should and who should not.

Consider

  • Adult patients (18+) with a documented clinical indication
  • Patients already self-administering cannabis through unmeasured rolled joints
  • Patients where oral cannabis is contraindicated or ineffective
  • Patients who would benefit from dose-controlled, audit-traceable supply

Do not prescribe

  • Pregnancy or breastfeeding
  • Active cardiovascular disease, recent MI, severe arrhythmia
  • Severe COPD or other significant respiratory disease
  • Active psychosis, schizophrenia, or significant family history
  • Under 18, or patients without capacity for informed consent
  • Patients who do not currently use combustible nicotine or cannabis (this is not a route for starting)
The prescription pathway

How it works, step by step.

  1. Clinical assessment

    Confirm indication, confirm absence of contraindications, confirm the patient understands this is a harm-reduction route, not a quit aid or safety claim.

  2. Issue the prescription

    Standard SAHPRA cannabis prescription form. Specify blend (anxiety, sleep, chronic pain), monthly pack count, and review interval. Prescription is tied to a dispensing pharmacy in the participating network.

  3. Patient collects at pharmacy

    The pharmacy verifies the script, dispenses the monthly allotment, and records the pack identifier against the patient record per SAHPRA cannabis controlled-substance requirements.

  4. Patient uses, audit trail builds

    Every pack carries a QR resolving to its specific cannabis and tobacco batch provenance. The patient can scan, the pharmacist can scan, the auditor can scan. The data is the same.

  5. Review

    At the prescribed review interval, clinical reassessment, indication review, dose adjustment, continue or discontinue.

Clinical resources

Detailed prescribing information available on request.

Mostly Rollie's is at concept stage. Full prescribing information, the SAHPRA registration dossier, the clinical safety summary, and the patient information leaflet will accompany the regulatory submission. Clinicians interested in pilot involvement or who have specific clinical questions can request a briefing.

Request a clinical briefing